PGC-1α expression is also negatively correlated with NAFLD severity in humans [81], but it remains to be seen whether this reflects a cause or a consequence of the mitochondrial abnormalities found in humans or whether targeting PGC-1α could be a viable option to treat the disease. The gene discussed is PPARGC1A; the disease is metabolic dysfunction-associated steatotic liver disease.